What is the 13F Pro Quality Score for RKDA?

13F Pro ranks Arcadia Biosciences, Inc. (RKDA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RKDA's current score at https://13fpro.ai/company/RKDA (free sign-up required for the full ranking).

Which hedge funds own the most RKDA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RKDA include HRT FINANCIAL, CITADEL ADVISORS, Virtu Financial. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/RKDA as soon as new 13F filings post.

Where does 13F Pro source RKDA data?

All Arcadia Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Arcadia Biosciences, Inc. files with the SEC under CIK 1469443. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RKDA in?

Arcadia Biosciences, Inc. (RKDA) is classified in the Energy sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/energy.

How often is RKDA research updated on 13F Pro?

RKDA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Arcadia Biosciences, Inc.(RKDA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Energy →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1469443 RKDA stock profile & AI dashboard →

13F Pro Quality Score

12.1/100

Rank #2,890 of 2,962 stocks

View Energy peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why RKDA Scores 12/100

exact factor attribution · 2026-09-11

RKDA's composite is held back by scale and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Shareholder dilution

-1.0 pts

30th pct

Institutional flow

-2.2 pts

6th pct

Earnings growth

-2.2 pts

5th pct

Earnings quality

-4.3 pts

7th pct

Capital efficiency

-4.8 pts

2th pct

Free cash flow

-5.2 pts

15th pct

Revenue growth

-5.4 pts

23th pct

Profitability

-6.0 pts

10th pct

Scale

-6.7 pts

5th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

RKDA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Arcadia Biosciences, Inc. (RKDA), a Energy sector company. 13F Pro's AI-powered ranking engine scores RKDA at 12.1/100 on a 32-signal composite quality model, placing it at rank #2,890 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Arcadia Biosciences, Inc. reports quarterly revenue of $1.4M, net income of $-6.3M. Top institutional holders of RKDA by reported 13-F value include HRT FINANCIAL, CITADEL ADVISORS, Virtu Financial, based on the most recent SEC filings. RKDA trades on the Nasdaq exchange and files with the SEC under CIK 1469443. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RKDA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Arcadia Biosciences, Inc. directly from SEC EDGAR. Arcadia Biosciences, Inc.'s 13F Pro composite quality score has ranged between 12 and 19 since 2026, currently 12.1 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q2 2026

$1.4M

Net Income

Q2 2026

$-6.3M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-3.7% YoY

$4.9MFY 2025

FY22 $7.4MFY23 $4.5MFY24 $5.0MFY25 $4.9M

Net Income

+66.8% YoY

$-2.3MFY 2025

FY22 $-15.4MFY23 $-14.0MFY24 $-7.0MFY25 $-2.3M

Operating Income

+31.5% YoY

$-2.5MFY 2025

FY22 $-14.0MFY23 $-6.1MFY24 $-3.6MFY25 $-2.5M

EPS (Diluted)

+66.9% YoY

$-1.71FY 2025

FY22 $-25.65FY23 $-11.29FY24 $-5.17FY25 $-1.71

Total Assets

-51.6% YoY

$6.5MFY 2025

FY22 $28.9MFY23 $19.7MFY24 $13.5MFY25 $6.5M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

+50.8% YoY

$-4.7MFY 2025

FY22 $-14.0MFY23 $-15.3MFY24 $-9.6MFY25 $-4.7M

Free Cash Flow

+50.9% YoY

$-4.7MFY 2025

FY22 $-14.0MFY23 $-15.3MFY24 $-9.6MFY25 $-4.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$4.9M -3.7%	$5.0M +13.3%	$4.5M -40.0%	$7.4M +9.4%	$6.8M -15.6%	$8.0M
Net Income	$-2.3M +66.8%	$-7.0M +49.7%	$-14.0M +9.1%	$-15.4M -4.9%	$-14.7M -214.9%	$-4.7M
Operating Income	$-2.5M +31.5%	$-3.6M +40.2%	$-6.1M +56.4%	$-14.0M +60.6%	$-35.5M -178.0%	$-12.8M
EPS (Diluted)	$-1.71 +66.9%	$-5.17 +54.2%	$-11.29 +56.0%	$-25.65 +6.9%	$-27.56	—
Total Assets	$6.5M -51.6%	$13.5M -31.4%	$19.7M -31.9%	$28.9M -34.1%	$43.9M -7.2%	$47.3M
Total Debt	—	—	—	—	$0.00 -100.0%	$3.2M
Operating Cash Flow	$-4.7M +50.8%	$-9.6M +37.1%	$-15.3M -9.4%	$-14.0M +46.0%	$-25.9M +14.4%	$-30.2M
Free Cash Flow	$-4.7M +50.9%	$-9.6M +37.0%	$-15.3M -8.9%	$-14.0M +47.7%	$-26.9M +17.4%	$-32.6M

Get alerted when RKDA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Arcadia Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RKDA

HRT FINANCIAL LP
$60.0K88,386 sh
CITADEL ADVISORS LLC
$16.1K23,738 sh
Virtu Financial LLC
$15.0K21,786 sh
StoneX Group Inc.
$11.3K13,682 sh
GEODE CAPITAL MANAGEMENT, LLC
$11.0K16,135 sh
XTX Topco Ltd
$10.5K15,475 sh
STATE STREET CORP
$8.2K12,146 sh
JANE STREET GROUP, LLC
$7.0K10,245 sh
VANGUARD CAPITAL MANAGEMENT LLC
$6.5K9,644 sh
Bullock Wealth Management Group
$749.001,000 sh

Fund	Value	Shares
HRT FINANCIAL LP	$60.0K	88,386
CITADEL ADVISORS LLC	$16.1K	23,738
Virtu Financial LLC	$15.0K	21,786
StoneX Group Inc.	$11.3K	13,682
GEODE CAPITAL MANAGEMENT, LLC	$11.0K	16,135
XTX Topco Ltd	$10.5K	15,475
STATE STREET CORP	$8.2K	12,146
JANE STREET GROUP, LLC	$7.0K	10,245
VANGUARD CAPITAL MANAGEMENT LLC	$6.5K	9,644
Bullock Wealth Management Group	$749.00	1,000

More Energy Companies

View all Energy →

ACDC

ProFrac Holding Corp.

AESI

Atlas Energy Solutions Inc.

AGIG

ABUNDIA GLOBAL IMPACT GROUP, INC.

Antero Midstream Corp

AMPY

Amplify Energy Corp.

AMR

Alpha Metallurgical Resources, Inc.

ANNA

AleAnna, Inc.

APA

APA Corp

Put RKDA on your watchlist

Track score changes the day Arcadia Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RKDA a good stock to buy?

13F Pro's AI-powered analysis of Arcadia Biosciences, Inc. (RKDA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Energy sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RKDA are available on the RKDA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RKDA is classified as a small company.

Which hedge funds own RKDA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RKDA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Arcadia Biosciences, Inc.'s investment landscape.